State Street
OBIO icon

State Street’s Orchestra BioMed OBIO Stock Holding History

State Street’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$720K Buy
169,410
+10,377
+7% +$44.2K ﹤0.01% 3565
2025
Q4 		$660K Buy
159,033
+58,300
+58% +$235K ﹤0.01% 3613
2025
Q3 		$250K Sell
100,733
-29,400
-23% -$81.1K ﹤0.01% 3844
2025
Q2 		$349K Sell
130,133
-343,586
-73% -$1M ﹤0.01% 3694
2025
Q1 		$2.03M Buy
473,719
+26,007
+6% +$129K ﹤0.01% 3244
2024
Q4 		$1.79M Buy
447,712
+18,099
+4% +$97.2K ﹤0.01% 3351
2024
Q3 		$2.21M Buy
429,613
+47,308
+12% +$309K ﹤0.01% 3297
2024
Q2 		$3.12M Buy
382,305
+127,358
+50% +$738K ﹤0.01% 3131
2024
Q1 		$1.34M Sell
254,947
-30,963
-11% -$210K ﹤0.01% 3397
2023
Q4 		$2.61M Buy
285,910
+106,029
+59% +$724K ﹤0.01% 3227
2023
Q3 		$1.57M Buy
179,881
+38,044
+27% +$256K ﹤0.01% 3418
2023
Q2 		$993K Buy
141,837
+107,651
+315% +$1.63M ﹤0.01% 3581
2023
Q1 		$669K Buy
+34,186
New +$396K ﹤0.01% 3651

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

State Street's OBIO Position: Q1 2026 in Review

State Street increased its Orchestra BioMed (OBIO) stake by 6.5% in Q1 2026, buying an estimated $44.2K and bringing the position to 169,410 shares worth $720K. The position accounts for ﹤0.01% of the portfolio, ranked #3565.

State Street first reported a position in OBIO in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.12M in Q2 2024. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • State Street held 169,410 shares of Orchestra BioMed worth $720K as of Q1 2026.
  • State Street bought 10,377 Orchestra BioMed shares in Q1 2026, an estimated $44.2K.
  • Orchestra BioMed made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3565 holding.
  • State Street first reported a position in Orchestra BioMed in Q1 2023 and has held it in 13 quarters since.
  • State Street's Orchestra BioMed position peaked at $3.12M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.